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1. The role of arginine-vasopressin (AVP) in the maintenance of high blood pressure in rats with deoxycorticosterone acetate (DOCA) hypertension was investigated.
2. Plasma concentrations of AVP were significantly elevated in DOCA hypertensive rats compared with normotensive control rats, whether or not they received 1% sodium chloride solution or demineralized water to drink.
3. The specific antagonist of the vasopressor response to AVP, d(CH,),VDAVP (100 pg/kg intravenously), significantly increased cardiac output and decreased total peripheral resistance, but had no effect on mean arterial pressure in DOCA hypertensive rats. No changes of mean arterial pressure, cardiac output and total peripheral resistance were observed in the normotensive control groups after d(CH,),VDAVP.
4. After sino-aortic baroreceptor deafferentation, d(CH,),VDAVP decreased mean arterial pressure in DOCA-salt hypertensive rats, but not in the control groups. Plasma concentrations of AVP were measured after 4 weeks of treatment in 10 animals from each group by a radioimmunoassay which was recently developed in our laboratory and is described in detail elsewhere [71. In eight animals from each group haemodynamic measurements were performed. Catheters were implanted 1 day before the experiment into the femoral artery and into the femoral vein. The next morning rats were again anaesthetized with ether and a catheter (PE 10) was introduced into the right jugular vein with the tip placed in front of the right atrium. The left carotid artery was also cannulated and a thermistor probe with an external diameter of 0:6 mm was introduced into the aorta so that the tip lay in the main blood stream of the aortic arch. At least 4 h after completion of surgery, arterial blood pressure and cardiac output were measured in the conscious unrestrained rats. Cardiac output was determined by the thermodilution method [8, 91, a computer with an automatic calculation of the dilution curve (HMV 7905, Hoyer Co., Bremen, F.R.G.) being used. A bolus of 0.2 ml of 0.9% sodium chloride solution at room temperature (20-22°C) was injected into the right atrium. Control values of cardiac output were determined twice within 5 min; 10 min later the vasopressin antagonist d(CH,),VDAVP was injected (100 pg/kg) into the femoral vein, 0.5 and 5 min after which cardiac output measurements were repeated.
It is concluded that elevated circulating
The effect of d(CH,),VDAVP on blood pressure was studied in rats with bilateral SAD (n = 20) performed by the procedure described by Krieger I101 and in rats submitted to a sham operation (n = 17). One week after recovery from the surgical procedure treatment with DOCA + 1% sodium chloride solution or sham treatment + 1% sodium chloride solution was performed as described above. In these rats catheters were implanted into the femoral artery and vein the day before the experiment. Mean arterial pressure was measured at exactly 5 min intervals during 1 h (i.e. 12 different time points) because of the variability of blood pressure in rats with SAD [ 111. An average mean arterial pressure for each rat was calculated from individual measurements.
Results are given as means f SEM. Significance of differences was assessed by Student's paired t-test or by analysis of variance followed by Scheffe's test when statistical significance for the mean effect was reached.
Results
Plasma concentrations of AVP were significantly higher in rats treated for 4 weeks with DOCA than in normotensive control rats (DOCA + saline: 8.42 f 1.32 fmol/ml; saline: 4.33 f 0-47 fmol/ml, P < 0.05; DOCA + water:
7.88 f 0.62 fmol/ml; water: 3.30 f 0.23 fmol/ml, P < 0.05). Intravenous administration of the antagonist of the vasopressor action of AVP [d(CH,),VDAVP] in a dose of 100 pg/kg to both groups of DOCA-treated rats increased cardiac output and decreased total peripheral resistance, but had no effect on mean arterial blood pressure (Table 1 ). In the control groups, not treated with DOCA, no changes of mean arterial pressure, cardiac output and total peripheral resistance were observed after administration of d(CH,),VDAVP (Table 1) .
In DOCA-saline-treated rats with SAD mean arterial pressure rose to 156 f 3.2 mmHg (n = 10) after 4 weeks of treatment as compared with 147 f 6.7 mmHg (n = 8) in sham-operated DOCA-saline-treated rats (P > 0.05). In the baroreceptor-denervated control group mean arterial pressure was slightly but not significantly higher (121 f 4.4 mmHg, n = 9) than in the sham-operated control group (108 f 2.8 mmHg, n = 9, P > 0.05). The variability of blood pressure (SD of 12 measurements) was significantly higher in rats with SAD (DOCA: 14.6 f 2-5; control: 10.0 1.1) than in the' sham-operated rats (DOCA-: 6-8 f 0.7; control: 4.5 k 0.2) (P < 0.05 respectively).
In DOCA-saline-treated rats with SAD intravenous administration of d(CH,),VDAVP elicited a fall in mean arterial pressure of 22.4 f 5.8 mmHg (P < 0.01); no change of blood pressure occurred in the three other groups studied (sham-operated DOCA: -1.0 f 1.1 mmHg; SAD control group: 0.7 f 1-1 mmHg; sham-operated control groups: 0.4 f 1.8 mmHg).
Discussion
The results of this study demonstrate that circulating AVP is elevated in DOCA hypertensive rats. An increase of plasma AVP levels in DOCA hypertensive rats which had received saline as drinking fluid has previously been reported [ 11. In our experiments this finding is confirmed and extended by the observation of a similar elevation of circulating AVP in DOCAtreated rats independently of whether the rats received demineralized water or saline as drinking fluid.
The two-to three-fold elevation of endogenous AVP in DOCA hypertension has significant vasoconstrictor effects, since the intravenous administration of a specific antagonist of the AVP receptors at the vascular smooth muscle resulted in a reduction of total peripheral resistance. This vasodilator effect of the AVP antagonist d(CH,),VDAVP in DOCA hypertensive rats is accompanied by an increase in cardiac output with the result that mean blood pressure is not affected. This clearly indicates that circulating AVP participates in the elevation of total peripheral resistance in this experimental model of hypertension. In the intact rat the AVP-induced vasoconstriction appears to be counter-regulated, however, by a subsequent reduction in cardiac output.
Recently, Montani et al.
[ 5 ] reported that intravenous infusion of AVP, in doses which do not affect blood pressure, decreased cardiac output and increased total peripheral resistance in conscious dogs. Our results reported here are in agreement with this finding. In the study of Montani et al. [51 it has also been shown that exogenous AVP in low concentrations led to significant increases of blood pressure, in baroreceptor-denervated dogs, confirming that the decrease of cardiac output and stability of arterial pressure in intact animals resulted from an activation of the baroreceptor reflex during AVP infusion.
We have therefore also studied the blood pressure responses to d(CH,),VDAVP in DOCA hypertensive rats with SAD. In these rats mean arterial pressure indeed decreased when the vasopressor action of AVP was antagonized by d(CH,),VDAVP. Similar results have been obtained with d(CH,),AVP, another AVP pressor antagonist, which decreased mean arterial pressure and total peripheral resistance with no change in cardiac output in DOCA-treated rats with SAD (unpublished observation). These results thus confirm that rats with SAD do not counter-regulate by an increase in cardiac output the decrease of total peripheral resistance after blockade of AVP vasoconstriction and thus cannot maintain the elevated blood pressure.
In DOCA hypertension AVP has vasoconstrictor effects and increases total peripheral resistance. In intact rats this is counter-regulated by an activation of the baroreceptor reflex and subsequent reduction in cardiac output. Therefore in rats with intact baroreceptor afferents the role of AVP as a vasoconstrictor agent is obscured by its sensitizing effect on the counterregulatory baroreceptor reflex mechanism. The latter effect may explain why Rabito et al. [121 did not observe a fall in blood pressure using two different AVP antagonists in DOCA and renal hypertensive rats. Our findings are in contrast to the dramatic decrease of blood pressure after intravenous administration of a specific AVP antiserum in intact DOCA-treated rats 111.
